(Yes, really.) That means generic semaglutide the active ingredient in Ozempic and Wegovy could be hitting the Canadian market sooner than expected
Analysis of weight management trials found that only 4.3% of participants permanently discontinued semaglutide 2.4 mg due to gastrointestinal adverse events, with most discontinuations occurring during the dose escalation phase
The disadvantages are slightly lower efficacy and the requirement for daily use rather than weekly injections. GLP-1 medications work by suppressing appetite
Individual response varies enormously based on body weight, metabolic factors, receptor sensitivity, and tolerance from prior medication use
Wegovy (semaglutide) is FDA-approved to help with long-term weight management in adults and in teens 12 and older with obesity
The FDA Adverse Event Reporting System (FAERS) contains reports of musculoskeletal complaints associated with GLP-1 use, but such reports do not prove causation and may reflect coincidental associations or other contributing factors